Inogen (NASDAQ:INGN) Stock Rating Lowered by Wall Street Zen

Inogen (NASDAQ:INGN – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday, Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Inogen in a report on Tuesday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy”.

Read Our Latest Analysis on INGN

Inogen Price Performance

Shares of NASDAQ INGN opened at $5.69 on Friday. Inogen has a 52 week low of $5.05 and a 52 week high of $7.67. The firm’s fifty day moving average is $6.00 and its 200 day moving average is $6.22. The company has a market cap of $147.94 million, a price-to-earnings ratio of -4.34 and a beta of 1.51.

Inogen (NASDAQ:INGN – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The medical technology company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.42). The firm had revenue of $77.19 million for the quarter, compared to the consensus estimate of $92.25 million. Inogen had a negative net margin of 10.46% and a negative return on equity of 19.29%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of INGN. Integrated Wealth Concepts LLC grew its holdings in shares of Inogen by 18.3% during the 2nd quarter. Integrated Wealth Concepts LLC now owns 16,728 shares of the medical technology company’s stock worth $108,000 after acquiring an additional 2,585 shares during the period. Steward Partners Investment Advisory LLC raised its position in shares of Inogen by 1.8% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 205,181 shares of the medical technology company’s stock worth $1,081,000 after acquiring an additional 3,650 shares in the last quarter. Moore Capital Management LP raised its position in shares of Inogen by 3.3% in the 2nd quarter. Moore Capital Management LP now owns 289,128 shares of the medical technology company’s stock worth $1,865,000 after acquiring an additional 9,229 shares in the last quarter. Royce & Associates LP purchased a new position in shares of Inogen in the 3rd quarter valued at approximately $77,000. Finally, IMC Chicago LLC purchased a new position in shares of Inogen in the 2nd quarter valued at approximately $95,000. Institutional investors own 89.94% of the company’s stock.

Inogen Company Profile

(Get Free Report)

Inogen, Inc. is a medical technology company focused on respiratory care. It develops, manufactures and markets oxygen concentrators and related products for people who require supplemental oxygen, including those with chronic respiratory conditions. Its products include the Inogen One line of portable oxygen concentrators, stationary oxygen concentrators and accessories. The company sells through direct-to-consumer channels and healthcare providers. Founded in 2001 and headquartered in Goleta, California, Inogen serves customers in the United States and international markets.

Further Reading

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.